|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||8.31 - 9.00|
|52 Week Range||7.07 - 16.00|
|Beta (5Y Monthly)||2.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 5, 2019 - Aug 9, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Cannabis stocks headed lower Tuesday after a Monday communication from the FDA, which sent warning letters to 13 companies for illegally selling products containing containing cannabidiol (CBD), violating the Federal Food, Drug, and Cosmetic Act. The 15 companies were warned for marketing CBD products for therapeutic uses in humans and/or animals as well as as dietary supplements. The FDA continues to maintain a strict stance on regulating the consumer CBD market, Bank of America Merrill Lynch analyst Christopher Carey said in his review of the dual communications from the FDA.
New guidelines issued in the United Kingdom for the consumption and prescription of cannabis issued by the National Institute for Health Care and Excellence fell short of expectations, according to Cantor Fitzgerald. The guidelines are an example of the challenges that Canadian LPs and others could face in key European markets, analyst Pablo Zuanic said in a Tuesday note. This translates to only 8,000 to 9,000 patients out of a population of 500,000 who suffer from other types of epilepsy in the U.K., the analyst said.
GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) announced Sunday that two of its medicines have been recommended by the U.K.’s National Institute for Health and Care Excellence to receive routine reimbursement from the National Health Service. Epidiolex, known as Epidyolex in Europe, and Sativex were approved by the NHS for the treatment of epilepsy and multiple sclerosis, respectively. Doctors will be able to prescribe Epidyolex, an oral CBD solution, for children with two types of severe epilepsy, Lennox Gastaut syndrome and Dravet syndrome.
Cronos Group Inc (NASDAQ: CRON ) shares are moving in premarket trading after reporting profitable earnings that missed Wall Street revenue estimates. It’s the greenest week of earnings: after CRON, a ...
GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) reported better-than-expected third-quarter revenues , thanks to strong sales of its cannabinoid epilepsy drug Epidiolex. The Analyst Bank of America analyst ...
Dow Jones futures signal another stock market rally pause. Xerox is mulling an HP takeover. Match Group is plunging on guidance. Roku, Carvna earnings are due.
GW Pharmaceuticals stock collapsed after the biotech company reported $91 million in sales for its third quarter ended Sept. 30. That beat expectations for $87 million in quarterly sales.
GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) shares are down after the company released its third-quarter earnings report Tuesday afternoon. Net sales for the company's lead product, Epidiolex, came in at $86.1 million. Receptivity to the introduction of this breakthrough treatment continues to be highly encouraging as a result of positive physician and patient experiences as well as strong payer coverage,” CEO Justin Gover said.
GW Pharmaceuticals (NASDAQ: GWPH ) releases its next round of earnings this Tuesday, November 5. Get the latest predictions in Benzinga's essential guide to the company's Q4 earnings report. Earnings and ...
On CNBC's "Mad Money Lightning Round," Jim Cramer said Xilinx, Inc. (NASDAQ: XLNX ) has too much exposure to China. Cramer advised a viewer with a long position in Occidental Petroleum Corporation ...
Brexit remains a great unknown. Now delayed until Jan. 31, 2020, one among the few certainties is that it has a huge potential impact on UK industries operating in Europe, and vice versa. While the UK's CBD market is huge, the fact that UK hemp farmers are prohibited from processing flowers and leaves from their crops requires them to rely on imports to sustain that market.
Charlotte's Web Holdings (TSE: CWEB) is one of the more high-profile manufacturers of CBD oil and supplements in the U.S. Featured on Sanja Gupta's CNN documentary, Weed, Charlotte's Web was initially a medical cannabis company but quickly pivoted to producing hemp-derived CBD. In 2018, the company reported annual revenue of $69.5 million. Specializing in CBD oils and tinctures, the company reported annual revenue of $48.2 million in 2018.
Investors have pummeled GW stock recently, an analyst said, following recent concerns over prescriptions of its CBD oil, Epidiolex. Data suggest prescriptions slowed in early October.
On CNBC's "Mad Money Lightning Round," Jim Cramer said he doesn't understand how New Relic Inc (NYSE: NEWR ) could have such a degradation. Leidos Holdings Inc (NYSE: LDOS ) is a winner and it ...
Thirteen analysts are covering GW Pharmaceuticals in October. Nine covered the stock in October 2018. The consensus target price for the stock is $226.85.
Epidiolex was launched last November as the first cannabis medicine approved in the U.S. Shares of GW Pharmaceuticals have slumped, even though sales of the drug are soaring. The stock could go even lower.
Cannabis Countdown: Top 10 Marijuana Stock News Stories of the Week Welcome to the Cannabis Countdown . In this week’s rendition, we’ll recap and countdown the top 10 marijuana stock news stories for ...
Oppenheimer cut its stock price target for GW Pharmaceuticals PLC on Friday, after a poll of 25 prescribers of the company's Epidiolex, the only cannabis-based drug to win U.S. Food and Drug Administration approval as a treatment for severe forms of epilepsy. Analysts Esther Rajavelu and Benjamin Fages lowered their 2019 to 2020 revenue forecasts based on new patient acquisition rates and dosing regiments, increased their mid-term revenue forecast -- defined as for 2021 to 2024 -- based on a higher proportion of maintenance patients versus new ones, and lowered their long-term revenue forecasts -- for the 2025 to 2030 period -- based on gradually rising attrition rates and a declining net price. "These changes lower our PT to $233 from $239, and we maintain our outperform rating as we believe Epidiolex US uptake continues to progress well, and we await management comments on EU pricing/commercial strategy," the analysts wrote in a note to clients. The third-quarter forecast assumes 3,400 new patients for the drug, raising the total to 15,400 from 12,000 in the second quarter. Shares were up 0.4% in premarket trade, and have gained 29% in 2019, while the ETFMG Alternative Harvest ETF has fallen 12% and the S&P 500 has gained 19%.
Epidiolex is the only CBD-approved treatment for childhood-onset epilepsy, and its products will be introduced to 28 countries across Europe in the coming years, Gover said during a "Mad Money" interview Tuesday.
GW Pharmaceuticals has announced the European Commission's approval of EPIDYOLEX. This will mark its entry into all European countries, including the UK.
In his second "Executive Decision" segment of Mad Money Tuesday night, Jim Cramer sat down with Justin Gover, CEO of GW Pharmaceuticals Plc , which has dropped nearly 14% this week as the cannabis stocks have fallen out of favor on Wall Street. Gover said that GW Pharmaceuticals is in the best shape it's ever been. Epidiolex, the company's epilepsy seizure drug, is now available in 28 countries and is addressing the needs of 500,000 patients that suffer from seizures.
GW Pharmaceuticals stock initially popped, then fell, Monday after European regulators approved the biotech company's cannabidiol oil, a medicine called Epidyolex, in two seizure disorders.
GW Pharma said the European Commission has approved the marketing authorization for Epidiolex as an adjunctive therapy of seizures associated with Lennox-Gastaut syndrome, or LGS, or Dravet syndrome, or DS, in conjunction with clobazam, for treating patients two years of age and older.
GW Pharmaceuticals PLC shares rose 3.9% in premarket trade Monday, after the company said it has received European Commission approval for its cannabis-based drug Epidyolex for the treatment of seizures in patients with Lennox-Gastaut syndrome or Dravet syndrome, in conjunction with clobazam, two severe types of childhood epilepsy. The drug, which is already approved in the U.S. under the brand name Epidiolex, will now be available to children of 2 years of age and older across Europe. The news "marks a significant milestone, offering patients and their families the first in a new class of epilepsy medicines and the first and only EMA-approved CBD medicine to treat two severe and life-threatening forms of childhood-onset epilepsy," Chief Executive Justin Gover said in a statement. The approval is based on the results from four randomised, controlled phase 3 trials, involving more than 714 patients. GW Pharma shares have gained 32% in 2019, while the S&P 500 has gained 19%.